Effects of Ojeok-san on the Pharmacokinetics of Celecoxib at Steady-state in Healthy Volunteers

Sang In Park, Ji-Young Park, Min Ju Park, Sung Vin Yim, Bo Hyung Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Ojeok-san is a frequently used herbal medication for the management of osteoarthritic pain. We evaluated the effect of Ojeok-san on the pharmacokinetics of celecoxib at steady-state in healthy individuals. An open-label, fixed-sequence, two-period, two-treatment cross-over study was conducted. In period I, the individuals received celecoxib capsule 200 mg once daily for 4 days. In period II, only Ojeok-san (14.47 g/pack, three times daily) was administered for 4 days, followed by co-administration with celecoxib for 4 days. On the fourth (final) day of administration, Ojeok-san was administered as a single dose. The blood samples for pharmacokinetic evaluation were collected for up to 48 hr after the administration of celecoxib in each study period. Of the 22 enrolled individuals, 20 individuals completed the study. In the presence of Ojeok-san, the systemic exposure of celecoxib was decreased. The geometric mean ratios ([celecoxib + Ojeok-san]/celecoxib) and the 90% confidence intervals for the maximum plasma concentration (Cmax) and the area under the plasma concentration–time curve during dosing interval (AUCτ) of celecoxib at steady-state were 0.725 (0.620–0.848) and 0.885 (0.814–0.962), respectively. The changes in the mean of the Cmax and AUCτ of celecoxib were greater in intermediate metabolizers of cytochrome 2C9 (CYP2C9) than in normal metabolizers. Our results suggested that the Cmax and AUCτ of celecoxib were reduced by Ojeok-san co-administration. This finding may be beneficial to determine the required adjustment of celecoxib dosage when co-administered with Ojeok-san.

Original languageEnglish
Pages (from-to)51-57
Number of pages7
JournalBasic and Clinical Pharmacology and Toxicology
Volume123
Issue number1
DOIs
Publication statusPublished - 2018 Jul 1

Fingerprint

Celecoxib
Pharmacokinetics
Healthy Volunteers
Area Under Curve
ojeok-san
Plasmas

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

Effects of Ojeok-san on the Pharmacokinetics of Celecoxib at Steady-state in Healthy Volunteers. / Park, Sang In; Park, Ji-Young; Park, Min Ju; Yim, Sung Vin; Kim, Bo Hyung.

In: Basic and Clinical Pharmacology and Toxicology, Vol. 123, No. 1, 01.07.2018, p. 51-57.

Research output: Contribution to journalArticle

Park, Sang In ; Park, Ji-Young ; Park, Min Ju ; Yim, Sung Vin ; Kim, Bo Hyung. / Effects of Ojeok-san on the Pharmacokinetics of Celecoxib at Steady-state in Healthy Volunteers. In: Basic and Clinical Pharmacology and Toxicology. 2018 ; Vol. 123, No. 1. pp. 51-57.
@article{5b155ccce3dd4a868731a7cb7b560b73,
title = "Effects of Ojeok-san on the Pharmacokinetics of Celecoxib at Steady-state in Healthy Volunteers",
abstract = "Ojeok-san is a frequently used herbal medication for the management of osteoarthritic pain. We evaluated the effect of Ojeok-san on the pharmacokinetics of celecoxib at steady-state in healthy individuals. An open-label, fixed-sequence, two-period, two-treatment cross-over study was conducted. In period I, the individuals received celecoxib capsule 200 mg once daily for 4 days. In period II, only Ojeok-san (14.47 g/pack, three times daily) was administered for 4 days, followed by co-administration with celecoxib for 4 days. On the fourth (final) day of administration, Ojeok-san was administered as a single dose. The blood samples for pharmacokinetic evaluation were collected for up to 48 hr after the administration of celecoxib in each study period. Of the 22 enrolled individuals, 20 individuals completed the study. In the presence of Ojeok-san, the systemic exposure of celecoxib was decreased. The geometric mean ratios ([celecoxib + Ojeok-san]/celecoxib) and the 90{\%} confidence intervals for the maximum plasma concentration (Cmax) and the area under the plasma concentration–time curve during dosing interval (AUCτ) of celecoxib at steady-state were 0.725 (0.620–0.848) and 0.885 (0.814–0.962), respectively. The changes in the mean of the Cmax and AUCτ of celecoxib were greater in intermediate metabolizers of cytochrome 2C9 (CYP2C9) than in normal metabolizers. Our results suggested that the Cmax and AUCτ of celecoxib were reduced by Ojeok-san co-administration. This finding may be beneficial to determine the required adjustment of celecoxib dosage when co-administered with Ojeok-san.",
author = "Park, {Sang In} and Ji-Young Park and Park, {Min Ju} and Yim, {Sung Vin} and Kim, {Bo Hyung}",
year = "2018",
month = "7",
day = "1",
doi = "10.1111/bcpt.12971",
language = "English",
volume = "123",
pages = "51--57",
journal = "Basic and Clinical Pharmacology and Toxicology",
issn = "1742-7835",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Effects of Ojeok-san on the Pharmacokinetics of Celecoxib at Steady-state in Healthy Volunteers

AU - Park, Sang In

AU - Park, Ji-Young

AU - Park, Min Ju

AU - Yim, Sung Vin

AU - Kim, Bo Hyung

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Ojeok-san is a frequently used herbal medication for the management of osteoarthritic pain. We evaluated the effect of Ojeok-san on the pharmacokinetics of celecoxib at steady-state in healthy individuals. An open-label, fixed-sequence, two-period, two-treatment cross-over study was conducted. In period I, the individuals received celecoxib capsule 200 mg once daily for 4 days. In period II, only Ojeok-san (14.47 g/pack, three times daily) was administered for 4 days, followed by co-administration with celecoxib for 4 days. On the fourth (final) day of administration, Ojeok-san was administered as a single dose. The blood samples for pharmacokinetic evaluation were collected for up to 48 hr after the administration of celecoxib in each study period. Of the 22 enrolled individuals, 20 individuals completed the study. In the presence of Ojeok-san, the systemic exposure of celecoxib was decreased. The geometric mean ratios ([celecoxib + Ojeok-san]/celecoxib) and the 90% confidence intervals for the maximum plasma concentration (Cmax) and the area under the plasma concentration–time curve during dosing interval (AUCτ) of celecoxib at steady-state were 0.725 (0.620–0.848) and 0.885 (0.814–0.962), respectively. The changes in the mean of the Cmax and AUCτ of celecoxib were greater in intermediate metabolizers of cytochrome 2C9 (CYP2C9) than in normal metabolizers. Our results suggested that the Cmax and AUCτ of celecoxib were reduced by Ojeok-san co-administration. This finding may be beneficial to determine the required adjustment of celecoxib dosage when co-administered with Ojeok-san.

AB - Ojeok-san is a frequently used herbal medication for the management of osteoarthritic pain. We evaluated the effect of Ojeok-san on the pharmacokinetics of celecoxib at steady-state in healthy individuals. An open-label, fixed-sequence, two-period, two-treatment cross-over study was conducted. In period I, the individuals received celecoxib capsule 200 mg once daily for 4 days. In period II, only Ojeok-san (14.47 g/pack, three times daily) was administered for 4 days, followed by co-administration with celecoxib for 4 days. On the fourth (final) day of administration, Ojeok-san was administered as a single dose. The blood samples for pharmacokinetic evaluation were collected for up to 48 hr after the administration of celecoxib in each study period. Of the 22 enrolled individuals, 20 individuals completed the study. In the presence of Ojeok-san, the systemic exposure of celecoxib was decreased. The geometric mean ratios ([celecoxib + Ojeok-san]/celecoxib) and the 90% confidence intervals for the maximum plasma concentration (Cmax) and the area under the plasma concentration–time curve during dosing interval (AUCτ) of celecoxib at steady-state were 0.725 (0.620–0.848) and 0.885 (0.814–0.962), respectively. The changes in the mean of the Cmax and AUCτ of celecoxib were greater in intermediate metabolizers of cytochrome 2C9 (CYP2C9) than in normal metabolizers. Our results suggested that the Cmax and AUCτ of celecoxib were reduced by Ojeok-san co-administration. This finding may be beneficial to determine the required adjustment of celecoxib dosage when co-administered with Ojeok-san.

UR - http://www.scopus.com/inward/record.url?scp=85048578897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048578897&partnerID=8YFLogxK

U2 - 10.1111/bcpt.12971

DO - 10.1111/bcpt.12971

M3 - Article

C2 - 29377603

AN - SCOPUS:85048578897

VL - 123

SP - 51

EP - 57

JO - Basic and Clinical Pharmacology and Toxicology

JF - Basic and Clinical Pharmacology and Toxicology

SN - 1742-7835

IS - 1

ER -